In conclusion, H3R was identified as a novel target for promotion of oligodendrocyte differentiation and remyelination in patients with MS via phenotypic screening, then validated by results of in vitro and in vivo models, and pathology of human samples of patients with MS. The gene discussed is HRH3; the disease is myeloid sarcoma.